| |
Cryptogenic HCC (n = 35)
|
HBV-HCC
|
* p
|
HCV-HCC
|
**p
|
ALC-HCC
|
***p
|
|---|
| | |
(n = 321)
| |
(n = 69)
| |
(n = 55)
| |
|---|
|
AFP (IU/mL)
| | |
0.036
| |
0.938
| |
0.116
|
|
<20
|
19 (57.6)
|
108 (34.4)
| |
33 (53.2)
| |
35 (70.0)
| |
|
20 ~ 200
|
4 (12.1)
|
78 (24.8)
| |
12 (19.4)
| |
8 (16.0)
| |
|
>200
|
10 (30.3)
|
128 (40.8)
| |
17 (27.4)
| |
7 (14.0)
| |
|
PVT
|
4 (11.4)
|
89 (27.7)
|
0.037
|
22 (31.9)
|
0.023
|
10 (18.2)
|
0.389
|
|
Extrahepatic metastasis
|
1 (2.9)
|
19 (5.9)
|
0.706
|
5 (7.2)
|
0.661
|
3 (5.5)
|
0.560
|
|
TNM stage
| | |
0.361
| |
0.889
| |
0.385
|
|
I
|
16 (45.7)
|
121 (37.7)
| |
34 (49.3)
| |
15 (27.3)
| |
|
II
|
5 (14.3)
|
57 (17.8)
| |
10 (14.5)
| |
20 (36.4)
| |
|
III
|
13 (37.1)
|
122 (38.0)
| |
20 (29.0)
| |
17 (30.9)
| |
|
IV
|
1 (2.9)
|
21 (6.5)
| |
5 (7.2)
| |
3 (5.5)
| |
|
BCLC stage
| | |
0.120
| |
0.380
| |
0.120
|
|
A
|
18 (51.4)
|
148 (46.1)
| |
38 (55.1)
| |
23 (41.8)
| |
|
B
|
11 (31.4)
|
65 (20.2)
| |
8 (11.6)
| |
15 (27.3)
| |
|
C
|
6 (17.1)
|
94 (29.3)
| |
20 (29.0)
| |
13 (23.6)
| |
|
D
|
0 (0)
|
14 (4.4)
| |
3 (4.3)
| |
4 (7.3)
| |
|
HCC nodules
| | |
0.026
| |
0.020
| |
0.002
|
|
1
|
26 (74.3)
|
171 (53.3)
| |
34 (49.3)
| |
20 (36.4)
| |
|
2 ~ 3
|
4 (11.4)
|
63 (19.6)
| |
14 (20.3)
| |
17 (30.9)
| |
|
≥4
|
5 (14.3)
|
87 (27.1)
| |
21 (30.4)
| |
18 (32.7)
| |
|
Largest tumor size
| | |
0.536
| |
0.517
| |
0.940
|
|
<2cm
|
10 (28.6)
|
73 (22.7)
| |
27 (39.1)
| |
15 (27.3)
| |
|
2 ~ 5cm
|
12 (34.3)
|
120 (37.4)
| |
17 (24.6)
| |
21 (38.2)
| |
|
>5cm
|
13 (37.1)
|
128 (39.9)
| |
25 (36.2)
| |
19 (34.5)
| |
|
Treatment modality
| | | | | | | |
|
Resection
|
4 (11.4)
|
45 (14.0)
|
0.801
|
7 (10.1)
|
0.841
|
8 (14.5)
|
0.672
|
|
RFA
|
9 (25.7)
|
111 (34.6)
|
0.349
|
28 (40.6)
|
0.135
|
15 (27.3)
|
0.871
|
|
TACE
|
28 (80.0)
|
262 (81.6)
|
0.820
|
54 (78.3)
|
0.837
|
46 (83.6)
|
0.660
|
|
PEI
|
1 (2.9)
|
10 (3.1)
|
1.000
|
2 (2.9)
|
1.000
|
1 (1.8)
|
1.000
|
|
Systemic chemotherapy
|
2 (5.7)
|
24 (7.5)
|
1.000
|
1 (1.4)
|
0.261
|
3 (5.3)
|
1.000
|
|
Sorafenib
|
3 (8.6)
|
25 (7.8)
|
0.747
|
7 (10.1)
|
1.000
|
6 (10.9)
|
0.719
|
|
Liver transplantation
|
0 (0.0)
|
6 (1.9%)
|
1.000
|
0 (0.0)
| |
1 (1.8%)
|
1.000
|
|
No treatment
|
2 (5.7)
|
35 (10.4)
|
0.558
|
7 (10.1)
|
0.714
|
7 (12.7)
|
0.473
|
- Data are expressed as the number (%). Values in bold, statistically significant (p < 0.05).
-
AFP, Alpha-fetoprotein; PVT, Portal vein thrombosis; BCLC, Barcelona Clinic Liver Cancer; HCC, Hepatocellular carcinoma; RFA, Radiofrequency ablation; TACE, Transarterial chemoembolization; PEI, Percutaneous ethanol injection; HBV-HCC, Hepatitis B-associated hepatocellular carcinoma; HCV-HCC, Hepatitis C-associated hepatocellular carcinoma; ALC-HCC, Alcohol-associated hepatocellular carcinoma.
- *p: Cryptogenic HCC vs. HBV-HCC.
- **p: Cryptogenic HCC vs. HCV-HCC.
- ***p: Cryptogenic HCC vs. ALC-HCC.
